Decision relating to filgrastim and methotrexate prefilled syringes

This was the subject of a consultation letter dated 21 December 2015.

The proposal was approved as consulted on. In summary, the effect of the decision is that:

• From 1 March 2016 there will be a reduction in the price and subsidy of both strengths of filgrastim prefilled syringes (Zarzio) supplied by Novartis; and
• From 1 July 2016 there will be a reduction in the price and subsidy of methotrexate prefilled syringes (Methotrexate Sandoz) supplied by Novartis.

Details of the decision

Filgrastim prefilled syringes (Zarzio)

• The price and subsidy for filgrastim prefilled syringes (Zarzio) supplied by Novartis will be reduced in Section B and Part II of Section H of the Pharmaceutical Schedule from 1 March 2016 as follows (ex-manufacturer, excluding GST):

• A new confidential rebate will apply to Zarzio, reducing the net price.
• Zarzio will have subsidy and delisting protection until 30 June 2018.
• No changes will be made to the Special Authority criteria in Section B of the Pharmaceutical Schedule, or the restriction to oncologists or haematologists in Part II of Section H of the Pharmaceutical Schedule (HML).

Methotrexate prefilled syringes (Methotrexate Sandoz)

• The price and subsidy for methotrexate prefilled syringes (Methotrexate Sandoz) supplied by Novartis will be reduced in Section B and Part II of Section H of the Pharmaceutical Schedule from 1 July 2016 as follows (ex-manufacturer, excluding GST):

• Methotrexate Sandoz will have subsidy and delisting protection until 30 June 2018.

Feedback received

We appreciate all of the feedback that we received and acknowledge the time people took to respond. All consultation responses received by 15 January 2016 were considered in their entirety in making a decision on the proposed changes. All responses were supportive of the proposal:

More information

If you have any questions about this decision, you can email us at enquiry@pharmac.govt.nz